$360.5B in 2025 drug sales lose US exclusivity by 2037

Blockbuster drugs by the year the first US generic or biosimilar can launch, sized by 2025 worldwide sales ($B).

OncologyImmunologyCardiometabolicVaccinesInfectious diseaseNeuroscienceOtherEstimated date

020406080

$20.3B20

Entresto$7.7B Stelara$6.1B Prolia$4.4B Xgeva$2.1B

$11.1B11

Farxiga$8.4B Pomalyst$2.7B

$17.7B18

Xtandi$6.0B Trulicity$4.3B Ibrance$4.1B Lynparza$3.3B

$73.1B73

Keytruda$31.7B Eliquis$14.4B Opdivo$10.1B Vyndaqel$6.4B Gardasil$5.2B Jakafi$3.1B Otezla$2.3B

$34.8B35

Darzalex$14.3B Ocrevus$8.4B Cosentyx$6.7B Repatha$3.0B Enbrel$2.2B

$3.6B4

$48.8B49

Dupixent$17.8B Imfinzi$6.1B Verzenio$5.7B Tremfya$5.2B Kisqali$4.8B Kesimpta$4.4B Descovy$2.8B Cabometyx$2.1B

$53.0B53

Ozempic$19.3B Wegovy$12.0B Tagrisso$7.3B Entyvio$6.0B Imbruvica$4.9B Calquence$3.5B

$17.6B18

$11.2B11

Prevnar 20$6.5B Ultomiris$4.7B

$50.8B51

Mounjaro$23.0B Biktarvy$14.3B Zepbound$13.5B

$18.6B19

Trikafta$10.3B Rinvoq$8.3B

2025’25

2026’26

2027’27

2028’28

2029’29

2030’30

2031’31

2032’32

2033’33

2034’34

2035’35

2036’36

2037’37

Pharma Patent Cliff by readouts.io Data checked 28 September 2026 · Explore all 45 drugs →